News & Perspective

May 08, 2009

May 08, 2009

H1N1 FLU BREAKING NEWS: Cases reach 2,500, Mexico's severe cases, concern about viral mixing, holding at phase 5

The World Health Organization (WHO) listed a global total of 2,500 confirmed cases of swine influenza H1N1 in 25 countries today. That total included 1,204 cases in Mexico, 896 cases in the United States (yesterday's number), 214 in Canada, 88 in Spain, and 34 in the United Kingdom. The death toll remains at 44, including 42 in Mexico and 2 in the United States. [WHO update 22]

Feb 03, 2009

Feb 03, 2009

Experts weigh new H5N1 vaccine strategies

(CIDRAP News) – At an Infectious Diseases Society of America (IDSA) symposium in Washington, DC, today on seasonal and pandemic influenza, a group of experts fielded questions from reporters on some of the new trends and emerging issues, including prepandemic strategies for H5N1 avian influenza vaccines, now that some countries are stockpiling them.

Jun 18, 2008

Jun 18, 2008

UN: Pandemic preparedness pays off, but threat remains

(CIDRAP News) – David Nabarro, influenza coordinator for the United Nations (UN), said during a press conference yesterday that the world is better prepared to respond to an influenza pandemic, but he added that continuing outbreaks in some countries are a reminder that a major threat remains.

Jun 16, 2008

Jun 16, 2008

Sanofi to give WHO 60 million doses of H5N1 vaccine

(CIDRAP News) – Sanofi Pasteur pledged today to give 60 million doses of H5N1 influenza vaccine over 3 years to the World Health Organization (WHO) for a planned stockpile to help poor countries in the event of an influenza pandemic.

Nov 30, 2007

Nov 30, 2007

UN: H5N1 responses improving, but threat persists

(CIDRAP News) – Many countries have improved their responses to H5N1 avian influenza outbreaks in poultry in the past year, but the disease remains entrenched in six countries, according to a new report from the United Nations and the World Bank.

Nov 15, 2007

Nov 15, 2007

THE PANDEMIC VACCINE PUZZLE Can we vaccinate enough people in time to matter?

Maryn McKennaContributing Writer

(CIDRAP News) – This in-depth article investigates the prospects for development of vaccines to head off the threat of an influenza pandemic posed by the H5N1 avian influenza virus. Its seven parts put advances in vaccine technology in perspective by illuminating the formidable barriers to producing an effective and widely usable vaccine in a short time frame.

Oct 31, 2007

Oct 31, 2007

THE PANDEMIC VACCINE PUZZLE Part 5: What role for prepandemic vaccination?

Editor's note: This is the fifth in a seven-part series investigating the prospects for development of vaccines to head off the threat of an influenza pandemic posed by the H5N1 avian influenza virus. The series puts promising advances in vaccine technology in perspective by illuminating the formidable barriers to producing large amounts of an effective and widely usable vaccine in a short time frame.

Oct 26, 2007

Oct 26, 2007

THE PANDEMIC VACCINE PUZZLE Part 2: Vaccine production capacity falls far short

Editor's note: This is the second in a seven-part series investigating the prospects for development of vaccines to head off the threat of an influenza pandemic posed by the H5N1 avian influenza virus. The series puts promising advances in vaccine technology in perspective by illuminating the formidable barriers to producing large amounts of an effective and widely usable vaccine in a short time frame.

Jun 19, 2007

Jun 19, 2007

FLU CONFERENCE COVERAGE Virus ownership claims could disrupt flu vaccine system

– TORONTO (CIDRAP News) – The continuing debate over developing countries' ability to afford pandemic-influenza vaccines has produced a disturbing complication: the possibility that Indonesia and other countries affected by H5N1 avian flu will assert legal ownership of the viral isolates on which the vaccines would be based.

Pages

by organization

Newsletter Sign-up

Get CIDRAP news and other free newsletters.

Sign up now»

OUR UNDERWRITERS

Unrestricted financial support provided by

Bentson Foundation Gilead 
Grant support for ASP provided by


bioMérieux

  Become an underwriter»